090729-Xention-web-top-#105

Welcome to Xention

Xention is developing novel therapies for the treatment of atrial fibrillation using its proprietary platform of ion channel drug discovery and development.

The Company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need.

In addition, we have established alliances with major pharmaceutical companies in areas outside our core interests.

 

 

home-small

home-image-b

Xention awarded £1.4m from Technology Strategy Board

24 July 2014

Xention awarded £1.4m from Technology Strategy Board to develop new medicines for atrial fibrillation
Read More


Xention and Servier announce cardiovascular collaboration

02 October 2013

Xention and Servier announce a cardiovascular collaboration to further develop a selective Kv1.5 modulator for the treatment of atrial fibrillation
Read More